DDInter1619 DDInter1771
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label],. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole.
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Ropinirole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Ropinirole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Melatonin
Melatonin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Ropinirole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Ropinirole {u} (Compound) downregulates {v} (Gene) PPP2R5E
PPP2R5E {u} (Gene) is downregulated by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Ropinirole {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Teriflunomide
Ropinirole {u} (Compound) downregulates {v} (Gene) PPP2R5E
PPP2R5E {u} (Gene) is downregulated by {v} (Compound) Lovastatin
Lovastatin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Ropinirole {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Melatonin
Melatonin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Ropinirole {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Ropinirole {u} (Compound) causes {v} (Side Effect) Urinary incontinence
Urinary incontinence {u} (Side Effect) is caused by {v} (Compound) Voriconazole
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Ropinirole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Niacin
Niacin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Ropinirole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Ropinirole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Melatonin (Compound) and Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ropinirole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ropinirole (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Ropinirole (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Ropinirole (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Lovastatin (Compound) and Lovastatin may lead to a major life threatening interaction when taken with Teriflunomide
Ropinirole (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Melatonin (Compound) and Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ropinirole (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ropinirole (Compound) causes Urinary incontinence (Side Effect) and Urinary incontinence (Side Effect) is caused by Voriconazole (Compound) and Voriconazole may lead to a major life threatening interaction when taken with Teriflunomide
Ropinirole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Niacin (Compound) and Niacin may lead to a major life threatening interaction when taken with Teriflunomide